295 related articles for article (PubMed ID: 15448016)
1. Identification of the fenretinide metabolite 4-oxo-fenretinide present in human plasma and formed in human ovarian carcinoma cells through induction of cytochrome P450 26A1.
Villani MG; Appierto V; Cavadini E; Valsecchi M; Sonnino S; Curley RW; Formelli F
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6265-75. PubMed ID: 15448016
[TBL] [Abstract][Full Text] [Related]
2. 4-oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines.
Villani MG; Appierto V; Cavadini E; Bettiga A; Prinetti A; Clagett-Dame M; Curley RW; Formelli F
Cancer Res; 2006 Mar; 66(6):3238-47. PubMed ID: 16540676
[TBL] [Abstract][Full Text] [Related]
3. Decrease in drug accumulation and in tumour aggressiveness marker expression in a fenretinide-induced resistant ovarian tumour cell line.
Appierto V; Cavadini E; Pergolizzi R; Cleris L; Lotan R; Canevari S; Formelli F
Br J Cancer; 2001 Jun; 84(11):1528-34. PubMed ID: 11384104
[TBL] [Abstract][Full Text] [Related]
4. Antimitotic effect of the retinoid 4-oxo-fenretinide through inhibition of tubulin polymerization: a novel mechanism of retinoid growth-inhibitory activity.
Appierto V; Tiberio P; Cavadini E; Casalini P; Cappelletti G; Formelli F
Mol Cancer Ther; 2009 Dec; 8(12):3360-8. PubMed ID: 19996280
[TBL] [Abstract][Full Text] [Related]
5. A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer.
Colombo N; Formelli F; Cantù MG; Parma G; Gasco M; Argusti A; Santinelli A; Montironi R; Cavadini E; Baglietto L; Guerrieri-Gonzaga A; Viale G; Decensi A
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1914-9. PubMed ID: 17035399
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of fenretinide metabolites N-[4-methoxyphenyl]retinamide (MPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (3-keto-HPR) on fenretinide molecular targets β-carotene oxygenase 1, stearoyl-CoA desaturase 1 and dihydroceramide Δ4-desaturase 1.
Poliakov E; Samuel W; Duncan T; Gutierrez DB; Mata NL; Redmond TM
PLoS One; 2017; 12(4):e0176487. PubMed ID: 28448568
[TBL] [Abstract][Full Text] [Related]
7. Involvement of c-Fos in fenretinide-induced apoptosis in human ovarian carcinoma cells.
Appierto V; Villani MG; Cavadini E; Lotan R; Vinson C; Formelli F
Cell Death Differ; 2004 Mar; 11(3):270-9. PubMed ID: 14647238
[TBL] [Abstract][Full Text] [Related]
8. Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide.
Sabichi AL; Modiano MR; Lee JJ; Peng YM; Xu MJ; Villar H; Dalton WS; Lippman SM
Clin Cancer Res; 2003 Jul; 9(7):2400-5. PubMed ID: 12855611
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases.
Illingworth NA; Boddy AV; Daly AK; Veal GJ
Br J Pharmacol; 2011 Feb; 162(4):989-99. PubMed ID: 21054342
[TBL] [Abstract][Full Text] [Related]
10. Fenretinide breast cancer prevention trial: drug and retinol plasma levels in relation to age and disease outcome.
Formelli F; Camerini T; Cavadini E; Appierto V; Villani MG; Costa A; De Palo G; Di Mauro MG; Veronesi U
Cancer Epidemiol Biomarkers Prev; 2003 Jan; 12(1):34-41. PubMed ID: 12540501
[TBL] [Abstract][Full Text] [Related]
11. Nuclear retinoid receptors are involved in N-(4-hydroxyphenyl) retinamide (Fenretinide)-induced gene expression and growth inhibition in HL-60 acute myeloid leukemia cells.
Ozpolat B; Tari AM; Mehta K; Lopez-Berestein G
Leuk Lymphoma; 2004 May; 45(5):979-85. PubMed ID: 15291358
[TBL] [Abstract][Full Text] [Related]
12. Role of retinoic acid receptor overexpression in sensitivity to fenretinide and tumorigenicity of human ovarian carcinoma cells.
Pergolizzi R; Appierto V; Crosti M; Cavadini E; Cleris L; Guffanti A; Formelli F
Int J Cancer; 1999 May; 81(5):829-34. PubMed ID: 10328240
[TBL] [Abstract][Full Text] [Related]
13. Analysis of gene expression identifies PLAB as a mediator of the apoptotic activity of fenretinide in human ovarian cancer cells.
Appierto V; Villani MG; Cavadini E; Gariboldi M; De Cecco L; Pierotti MA; Lambert JR; Reid J; Tiberio P; Colombo N; Formelli F
Oncogene; 2007 Jun; 26(27):3952-62. PubMed ID: 17213814
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinide.
Formelli F; Cavadini E; Luksch R; Garaventa A; Villani MG; Appierto V; Persiani S
Cancer Chemother Pharmacol; 2008 Sep; 62(4):655-65. PubMed ID: 18066548
[TBL] [Abstract][Full Text] [Related]
15. Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites.
Sabichi AL; Xu H; Fischer S; Zou C; Yang X; Steele VE; Kelloff GJ; Lotan R; Clifford JL
Clin Cancer Res; 2003 Oct; 9(12):4606-13. PubMed ID: 14555536
[TBL] [Abstract][Full Text] [Related]
16. Sphingosine kinase mediates resistance to the synthetic retinoid N-(4-hydroxyphenyl)retinamide in human ovarian cancer cells.
Illuzzi G; Bernacchioni C; Aureli M; Prioni S; Frera G; Donati C; Valsecchi M; Chigorno V; Bruni P; Sonnino S; Prinetti A
J Biol Chem; 2010 Jun; 285(24):18594-602. PubMed ID: 20404323
[TBL] [Abstract][Full Text] [Related]
17. 4-oxo-N-(4-hydroxyphenyl)retinamide: two independent ways to kill cancer cells.
Tiberio P; Cavadini E; Abolafio G; Formelli F; Appierto V
PLoS One; 2010 Oct; 5(10):e13362. PubMed ID: 20976277
[TBL] [Abstract][Full Text] [Related]
18. Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression.
Supino R; Crosti M; Clerici M; Warlters A; Cleris L; Zunino F; Formelli F
Int J Cancer; 1996 Feb; 65(4):491-7. PubMed ID: 8621233
[TBL] [Abstract][Full Text] [Related]
19. Comparison of N-(4-hydroxyphenyl)retinamide and all-trans-retinoic acid in the regulation of retinoid receptor-mediated gene expression in human breast cancer cell lines.
Kazmi SM; Plante RK; Visconti V; Lau CY
Cancer Res; 1996 Mar; 56(5):1056-62. PubMed ID: 8640761
[TBL] [Abstract][Full Text] [Related]
20. N-(4-hydroxyphenyl)retinamide: interactions with retinoid-binding proteins/receptors.
Sani BP; Shealy YF; Hill DL
Carcinogenesis; 1995 Oct; 16(10):2531-4. PubMed ID: 7586162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
